Rasappa Arumugham biography
Rasappa Arumugham Ph.D. is no longer serves as Chief Scientific Officer of the Company effective 12/31/2020.D serves as Chief Scientific Officer of the Company. serves as Chief Scientific Officer of the Company. He joined Ocugen in March 2017 as its Vice President, Research and Development. In March 2018, he was appointed as our Chief Scientific Officer. Prior to joining Ocugen, Dr. Arumugham worked at Soligenix, Inc. as Vice President, Biopharmaceutical Development from August 2014 to March 2017 where he led the pharmaceutical development and manufacturing of biologics, peptides and small molecules in support of injectable and topical formulations. He also served as the Principal Investigator for the development of a heat stable ricin vaccine program funded by the US government. He has over 30 years of diverse experience in leading biopharmaceutical research and development in the areas of discovery and preclinical research, formulation, analytical development, quality control, technology transfer and manufacturing. He has a proven track record in drug development, scale up, and technology transfer supporting commercialization of vaccines and biologics including Prevnar®, Prevnar®13, TetramuneTM, Meningitec® and Trumenba®. Previously, he served as the Head of Microbial Analytics at the Manufacturing Division at Merck & Co., Inc. from December 2011 to September 2013. Prior to joining Merck, Dr. Arumugham spent 25 years in various biologics/vaccines research and development positions of increasing responsibilities at Pfizer Inc. and Wyeth. Dr. Arumugham earned his Ph.D. and MSc in Biochemistry and BSC in Chemistry from the University of Madras, India.
What is the salary of Rasappa Arumugham?
As the Chief Scientific Officer of Ocugen Inc, the total compensation of Rasappa Arumugham at Ocugen Inc is $365,358. There are 3 executives at Ocugen Inc getting paid more, with Dr. Shankar Musunuri M.B.A., MBA, Ph.D. having the highest compensation of $780,673.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
How old is Rasappa Arumugham?
Rasappa Arumugham is 68, he's been the Chief Scientific Officer of Ocugen Inc since 2019. There are 1 older and 15 younger executives at Ocugen Inc. The oldest executive at Ocugen Inc is Prabhavathi Fernandes, 71, who is the Independent Director.
What's Rasappa Arumugham's mailing address?
Rasappa's mailing address filed with the SEC is C/O OCUGEN, INC., 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN,, PA, 19355.
Insiders trading at Ocugen Inc
Over the last 5 years, insiders at Ocugen Inc have traded over $18,069,176 worth of Ocugen Inc stock and bought 1,511,356 units worth $684,830 . The most active insiders traders include Shankar Musunuri, Junge Zhang, and Uday Kompella. On average, Ocugen Inc executives and independent directors trade stock every 21 days with the average trade being worth of $96,347. The most recent stock trade was executed by Junge Zhang on 14 June 2023, trading 200,278 units of OCGN stock currently worth $100,139.
What does Ocugen Inc do?
ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.
What does Ocugen Inc's logo look like?
Ocugen Inc executives and stock owners
Ocugen Inc executives and other stock owners filed with the SEC include:
-
Dr. Shankar Musunuri M.B.A., MBA, Ph.D.,
Co-Founder, Chairman & CEO -
Shankar Musunuri,
Chairman of the Board, Chief Executive Officer -
Sanjay S. Subramanian M.B.A.,
Chief Accounting Officer, CFO, Treasurer, Head of Corp. Devel. & Corp. Sec. -
Rasappa Arumugham,
Chief Scientific Officer -
Dr. Uday B. Kompella Ph.D.,
Co-founder & Independent Director -
Junge Zhang,
Independent Director -
Suha Taspolatoglu,
Independent Director -
Manish Potti,
Independent Director -
Ramesh Kumar,
Independent Director -
Uday Kompella,
Independent Director -
Prabhavathi Fernandes,
Independent Director -
Kirsten Castillo,
Independent Director -
Kelly Beck,
Vice President, Investor Relations and Administration and Corporate Secretary -
Vijay Tammara,
Senior Vice President - Regulatory and Quality -
Sanjay Subramanian,
Chief Financial Officer, Chief Accounting Officer, Treasurer -
Michael Shine,
Sr. VP of Commercial -
J. P. Gabriel,
Sr. VP of Manufacturing & Supply Chain -
Dr. Bruce D. Forrest B.S., M.B.A., M.D.,
Acting Chief Medical Officer & Vaccine Scientific Advisory Board Member -
Dr. Arun Upadhyay Ph.D.,
Head of Research, Devel. & Discovery -
Dr. Vijay Tammara,
Sr. VP of Regulatory & Quality -
Zara Gaudioso,
Head of HR -
Ken Inchausti,
Head of Investor Relations & Communications -
Jessica Crespo,
CAO/SVP, Finance -
Daniel Jorgensen,
Chief Medical Officer -
Frank Leo,
Director -
Marna C Whittington,
Director -
Huma Qamar,
Chief Medical Officer -
Arun Upadhyay,
See Remarks